Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation

Slides:

Advertisements

Similar presentations

In Stem Cell Transplantation by Limiting the Morbidity of Graft-versus-Host Disease Tolerance to Myeloablative Conditioning is Improved Nicolas Novitzky,

Advertisements

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for.

Treatment of Patients with Adult T Cell Leukemia/Lymphoma with Cord Blood Transplantation: A Japanese Nationwide Retrospective Survey Koji Kato, Ilseung.

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Early Human Herpesvirus Type 6 Reactivation after Allogeneic Stem Cell Transplantation: A Large-Scale Clinical Study Rémy Dulery, Julia Salleron, Anny.

Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia Scott R. Solomon, Connie A. Sizemore, Xu Zhang,

Haploidentical and Matched Sibling Donor Hematopoietic Cell Transplantation for Patients with HLA-Homozygous Haplotypes Junya Kanda, Kazuhiro Ikegame,

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular.

Absolute Lymphocyte Count on Day 30 Is a Surrogate for Robust Hematopoietic Recovery and Strongly Predicts Outcome after T Cell-Depleted Allogeneic Stem.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Fludarabine-Melphalan Conditioning for AML and MDS: Alemtuzumab Reduces Acute and Chronic GVHD without Affecting Long-Term Outcomes Koen Van Besien,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Christopher C. Dvorak, Rajni Agarwal, Gary V. Dahl, John J

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia Jennifer.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation Philippe Armand, Haesook T. Kim, Daniel.

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Elderly Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma: A Nationwide.

Busulfan/Melphalan/Antithymocyte Globulin Followed by Unrelated Donor Cord Blood Transplantation for Treatment of Infant Leukemia and Leukemia in Young.

Allogeneic Bone Marrow Transplantation from Unrelated Human T-Cell Leukemia Virus- I–negative Donors for Adult T-Cell Leukemia/Lymphoma: Retrospective.

Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation Lindsay G. Jensen, Tracey Stiller,

Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma George.

Anti-HLA Antibodies Other than Against HLA-A, -B, -DRB1 Adversely Affect Engraftment and Nonrelapse Mortality in HLA-Mismatched Single Cord Blood Transplantation:

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Fludarabine and 2-Gy TBI is Superior to 2 Gy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial

Comparison of Conditioning with Fludarabine/Busulfan and Fludarabine/Melphalan in Allogeneic Transplantation Recipients 50 Years or Older Koji Kawamura,

Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma:

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Effect of Body Mass Index on Mortality of Patients with Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation Willis H. Navarro, Fausto R.

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Possible Association between Obesity and Posttransplantation Complications Including Infectious Diseases and Acute Graft-versus-Host Disease Shigeo Fuji,

A Comparison of Outcomes for Cord Blood Transplantation and Unrelated Bone Marrow Transplantation in Adult Aplastic Anemia Yachiyo Kuwatsuka, Junya Kanda,

Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation for High-Risk Lymphoma and Chronic Lymphoblastic Leukemia Jingmei.

Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian.

CD34-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed, High-Risk Multiple Myeloma Eric Smith, Sean M. Devlin, Satyajit.

Myeloablative Transplantation using either Cord Blood or Bone Marrow leads to Immune Recovery, High Long-Term Donor Chimerism and Excellent Survival in.

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

What is quality in a transplant program?

Impact of Graft-versus-Host Disease on Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Leukemia-Lymphoma Focusing on Preconditioning Regimens:

Haplo-Cord Transplantation Using CD34+ Cells from a Third-Party Donor to Speed Engraftment in High-Risk Patients with Hematologic Disorders Mi Kwon,

Peripheral Blood Eosinophilia Has a Favorable Prognostic Impact on Transplant Outcomes after Allogeneic Peripheral Blood Stem Cell Transplantation Dong.

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Comparison of Outcomes for Pediatric Patients With Acute Myeloid Leukemia in Remission and Undergoing Allogeneic Hematopoietic Cell Transplantation With.

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.

Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents Moreno Festuccia, Kelsey Baker, Theodore.

Double-Unit Cord Blood Transplantation after Myeloablative Conditioning for Patients with Hematologic Malignancies: A Multicenter Phase II Study in Japan

Impact of the Direction of HLA Mismatch on Transplantation Outcomes in Single Unrelated Cord Blood Transplantation Junya Kanda, Yoshiko Atsuta, Atsushi.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Mammen Chandy Biology of Blood and Marrow Transplantation

Adult Dual Umbilical Cord Blood Transplantation Using Myeloablative Total Body Irradiation (1350 cGy) and Fludarabine Conditioning Junya Kanda, David.

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen Hisayuki Yokoyama,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Cryopreserved CD34+ Cell Dose, but Not Total Nucleated Cell Dose, Influences Hematopoietic Recovery and Extensive Chronic Graft-versus-Host Disease after.

Presentation transcript:

Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation Koji Kawamura, Hiroyuki Takamatsu, Takashi Ikeda, Tsunehiko Komatsu, Nobuyuki Aotsuka, Itsuto Amano, Go Yamamoto, Kentaro Watanabe, Yuju Ohno, Kosei Matsue, Yasuji Kouzai, Nobuhiro Tsukada, Ken Ishiyama, Naoyuki Anzai, Koji Kato, Ritsuro Suzuki, Kazutaka Sunami, Yoshinobu Kanda Biology of Blood and Marrow Transplantation Volume 21, Issue 7, Pages 1291-1298 (July 2015) DOI: 10.1016/j.bbmt.2015.02.015 Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidences of neutrophil (A) and platelet engraftment (B). Biology of Blood and Marrow Transplantation 2015 21, 1291-1298DOI: (10.1016/j.bbmt.2015.02.015) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Cumulative incidences of grade II to IV acute GVHD (A), grade III and IV acute GVHD (B), chronic GVHD (C), and extensive chronic GVHD (D). Biology of Blood and Marrow Transplantation 2015 21, 1291-1298DOI: (10.1016/j.bbmt.2015.02.015) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Nonrelapse mortality in 77 evaluable patients (A), comparison of CBT with and without planned tandem auto/RIC-CBT (B). Progression-free survival in 77 evaluable patients (C), comparison of CBT with and without favorable factors (more than PR before CBT and prior transplantation) (D). Overall survival in 86 patients (E), comparison of CBT with and without planned tandem auto/RIC-CBT (F). Overall survival in 86 patients (G) and progression-free survival in 77 evaluable patients (H), comparison of CBT with planned tandem auto/RIC-CBT for patients with response of more than PR before CBT and all others. Biology of Blood and Marrow Transplantation 2015 21, 1291-1298DOI: (10.1016/j.bbmt.2015.02.015) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Progression-free survival grouped according to the development of chronic GVHD by a landmark analysis at day 150 after cord blood transplantation. Biology of Blood and Marrow Transplantation 2015 21, 1291-1298DOI: (10.1016/j.bbmt.2015.02.015) Copyright © 2015 American Society for Blood and Marrow Transplantation Terms and Conditions